Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikulaa Parachuri

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Indian Journal of Ophthalmology|August 24, 2021
Commentary: Acute central serous chorioretinopathy - Treat early, observe longerNilesh Kumar, Nikulaa Parachuri, Ashish Sharma
Ophthalmology|March 2, 2021
Re: Kunimoto et al.: Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study (Ophthalmology. 2020:127:1331-1334)Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri
JAMA Ophthalmology|April 29, 2021
Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and EfficacyAshish Sharma, Nilesh Kumar, Nikulaa Parachuri
Journal of Pediatric Ophthalmology and Strabismus|March 14, 2024
Electroretinogram as a Screening Tool to Assess Vigabatrin-Induced Retinal Toxicity in Children With Infantile SpasmsSuruthi Nagarajan, Rajesh Prabu, Nikulaa Parachuri, et al.
Ophthalmology|August 29, 2023
Re: Zhang et al.: The biosimilar paradox: how anti-VEGF biosimilars will increase patient and overall healthcare costs (Ophthalmology. 2023;130:966-973)Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|October 14, 2021
Brolucizumab-early experience with early extended interval regime in chronic centre involved diabetic macular oedemaDebdulal Chakraborty, Soumen Mondal, Nikulaa Parachuri, et al.
Eye (London, England)|July 14, 2022
Biosimilar anti-VEGF-Yardsticks to ensure biosimilarityAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|December 10, 2025
Aflibercept vs ranibizumab biosimilars: manufacturing differences that might matter in the long runAshish Sharma, Francesco Bandello, Sanjay Bandyopadhyay, et al.
Eye (London, England)|October 30, 2021
The Port Delivery System with ranibizumab-journey of mitigating vitreous hemorrhageAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|May 26, 2022
Fear of safety compromise with biosimilar anti-VEGF-perception or truthAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Indian Journal of Ophthalmology|August 24, 2021
Commentary: Acute central serous chorioretinopathy - Treat early, observe longerNilesh Kumar, Nikulaa Parachuri, Ashish Sharma
Ophthalmology|March 2, 2021
Re: Kunimoto et al.: Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study (Ophthalmology. 2020:127:1331-1334)Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri
JAMA Ophthalmology|April 29, 2021
Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and EfficacyAshish Sharma, Nilesh Kumar, Nikulaa Parachuri
Journal of Pediatric Ophthalmology and Strabismus|March 14, 2024
Electroretinogram as a Screening Tool to Assess Vigabatrin-Induced Retinal Toxicity in Children With Infantile SpasmsSuruthi Nagarajan, Rajesh Prabu, Nikulaa Parachuri, et al.
Ophthalmology|August 29, 2023
Re: Zhang et al.: The biosimilar paradox: how anti-VEGF biosimilars will increase patient and overall healthcare costs (Ophthalmology. 2023;130:966-973)Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|October 14, 2021
Brolucizumab-early experience with early extended interval regime in chronic centre involved diabetic macular oedemaDebdulal Chakraborty, Soumen Mondal, Nikulaa Parachuri, et al.
Eye (London, England)|July 14, 2022
Biosimilar anti-VEGF-Yardsticks to ensure biosimilarityAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|December 10, 2025
Aflibercept vs ranibizumab biosimilars: manufacturing differences that might matter in the long runAshish Sharma, Francesco Bandello, Sanjay Bandyopadhyay, et al.
Eye (London, England)|October 30, 2021
The Port Delivery System with ranibizumab-journey of mitigating vitreous hemorrhageAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|May 26, 2022
Fear of safety compromise with biosimilar anti-VEGF-perception or truthAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Pageof 7